全文获取类型
收费全文 | 197349篇 |
免费 | 2433篇 |
国内免费 | 158篇 |
专业分类
耳鼻咽喉 | 1400篇 |
儿科学 | 7313篇 |
妇产科学 | 3676篇 |
基础医学 | 18692篇 |
口腔科学 | 2212篇 |
临床医学 | 14202篇 |
内科学 | 35608篇 |
皮肤病学 | 1156篇 |
神经病学 | 17408篇 |
特种医学 | 9628篇 |
外国民族医学 | 9篇 |
外科学 | 32737篇 |
综合类 | 2994篇 |
现状与发展 | 1篇 |
一般理论 | 21篇 |
预防医学 | 19608篇 |
眼科学 | 3414篇 |
药学 | 11411篇 |
中国医学 | 779篇 |
肿瘤学 | 17671篇 |
出版年
2023年 | 340篇 |
2022年 | 992篇 |
2021年 | 1404篇 |
2020年 | 741篇 |
2019年 | 944篇 |
2018年 | 22985篇 |
2017年 | 17982篇 |
2016年 | 20130篇 |
2015年 | 1727篇 |
2014年 | 1831篇 |
2013年 | 2031篇 |
2012年 | 8639篇 |
2011年 | 22668篇 |
2010年 | 19631篇 |
2009年 | 12195篇 |
2008年 | 20493篇 |
2007年 | 22768篇 |
2006年 | 1541篇 |
2005年 | 3018篇 |
2004年 | 4174篇 |
2003年 | 5001篇 |
2002年 | 3101篇 |
2001年 | 579篇 |
2000年 | 708篇 |
1999年 | 439篇 |
1998年 | 347篇 |
1997年 | 309篇 |
1996年 | 184篇 |
1995年 | 201篇 |
1994年 | 161篇 |
1993年 | 109篇 |
1992年 | 164篇 |
1991年 | 201篇 |
1990年 | 234篇 |
1989年 | 176篇 |
1988年 | 147篇 |
1987年 | 131篇 |
1986年 | 118篇 |
1985年 | 113篇 |
1984年 | 86篇 |
1983年 | 107篇 |
1982年 | 59篇 |
1980年 | 71篇 |
1979年 | 80篇 |
1978年 | 52篇 |
1977年 | 55篇 |
1975年 | 49篇 |
1974年 | 57篇 |
1938年 | 60篇 |
1932年 | 57篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
11.
12.
N. S. Hari Narayana Moorthy Sergio F. Sousa Maria J. Ramos Pedro A. Fernandes 《Medicinal chemistry research》2016,25(7):1340-1357
Farnesyltransferase (FTase) is one of the prenyltransferase family enzymes that catalyse the transfer of 15-membered isoprenoid (farnesyl) moiety to the cysteine of CAAX motif-containing proteins including Rho and Ras family of G proteins. Inhibitors of FTase act as drugs for cancer, malaria, progeria and other diseases. In the present investigation, we have developed two structure-based pharmacophore models from protein–ligand complex (3E33 and 3E37) obtained from the protein data bank. Molecular dynamics (MD) simulations were performed on the complexes, and different conformers of the same complex were generated. These conformers were undergone protein–ligand interaction fingerprint (PLIF) analysis, and the fingerprint bits have been used for structure-based pharmacophore model development. The PLIF results showed that Lys164, Tyr166, TrpB106 and TyrB361 are the major interacting residues in both the complexes. The RMSD and RMSF analyses on the MD-simulated systems showed that the absence of FPP in the complex 3E37 has significant effect in the conformational changes of the ligands. During this conformational change, some interactions between the protein and the ligands are lost, but regained after some simulations (after 2 ns). The structure-based pharmacophore models showed that the hydrophobic and acceptor contours are predominantly present in the models. The pharmacophore models were validated using reference compounds, which significantly identified as HITs with smaller RMSD values. The developed structure-based pharmacophore models are significant, and the methodology used in this study is novel from the existing methods (the original X-ray crystallographic coordination of the ligands is used for the model building). In our study, along with the original coordination of the ligand, different conformers of the same complex (protein–ligand) are used. It concluded that the developed methodology is significant for the virtual screening of novel molecules on different targets. 相似文献
13.
Valerie Iles 《Health care analysis》2016,24(2):105-118
This paper takes a somewhat slant perspective on flourishing and care in the context of suffering, death and dying, arguing that care in this context consists principally of ‘acts of work and courage that enable flourishing’. Starting with the perception that individuals, society and health care professionals have become dulled to death and the process of dying in Western advanced health systems, it suggests that for flourishing to occur, both of these aspects of life need to be faced more directly. The last days of life need to be ‘undulled’. Reflections upon the experiences of the author as carer and daughter in the face of her mother’s experience of death are used as basis for making suggestions about how care systems and professionals might better assist people in dealing with ‘the most grown up thing’ humans ever do, which is to die. 相似文献
14.
15.
16.
Coronavirus disease 2019 (COVID-19) has resulted in many challenges in patient care, especially among high-risk populations such as heart transplant recipients. Patients with heart transplant experience a significantly higher mortality rate with COVID-19 infection, and management is based on extrapolation from clinical trials done on nontransplant patients and from clinical experience. Here we report 4 cases of patients with heart transplant who presented with COVID-19 infection in late 2020. Patients presented with symptoms similar to those seen in the general population. All 4 patients were admitted to the hospital, and they were all treated with dexamethasone. In addition, 2 patients received remdesivir. Immunosuppressive medications were adjusted to maintain adequate levels of immunosuppression but at the same time allow for an adequate immune response against the infection. All patients were discharged alive from the hospital. We then performed a literature review on studies that included heart transplant patients who developed the infection and developed suggestions for a standardized management approach, which we share in this article. 相似文献
17.
Henry Havel Gregory Finch Pamela Strode Marc Wolfgang Stephen Zale Iulian Bobe Hagop Youssoufian Matthew Peterson Maggie Liu 《The AAPS journal》2016,18(6):1373-1378
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. 相似文献
18.
19.
M. Alexandra Friedman Charlotte M. Niznik Janelle R. Bolden Lynn M. Yee 《Journal of community health》2016,41(2):354-358
While peer support has been investigated in multiple clinical contexts, its application to the postpartum setting is unknown. The aim was to assess acceptability of a postpartum peer support program for women with diabetes. Observational survey-based needs assessment of forty low-income women with diabetes, receiving care at a major medical institution. Mean age and gravidity were 30.7 years and 3.15 ± 1.67 respectively. 45 % expressed interest in a “buddy.” There was no significant difference between groups desiring and not desiring this program. A majority of respondents desired telephone, text messaging, and in-person contacts (79.2, 72.1, 83.8 %), with 72.5 % of patients desiring diabetes-related activities during clinic waiting time. Many women desire a postpartum diabetes reciprocal peer program for support outside of clinician visits. Patients are receptive to educational services during their wait and outside of clinic time, a potentially valuable opportunity to share important health information. 相似文献
20.
Huda Mohammed Alkreathy Mayson H. Alkhatib Safaa Ahmed Al Musaddi Khadijah Saeed A. Balamash Nadia Nour Osman Aftab Ahmad 《Clinical and experimental pharmacology & physiology》2019,46(5):496-505
Doxorubicin (DOX) is the most commonly used anticancer drug; however, it has limited use because prolonged administration may result in severe cardiotoxicity. Simvastatin (SIM), generally prescribed for hypercholesterolaemia, has also shown salubrious results in the monotherapy or combinational drug therapy of different cancers in various models. Nanoparticle drug delivery systems are a novel way of improving therapeutics and also improving the absorption and specificity of drugs towards tumour cells. In this study, we exploited this technology to increase drug specificity and minimize imminent adverse effects. In this study, the antitumour activity of the combination formulas of DOX and SIM, either loaded in water (DOX‐SIM‐Solution) or nanoemulsions (NEs) (DOX‐SIM‐NE), was evaluated in a Swiss albino mouse model of Ehrlich ascites carcinoma. The anticancer effect was assessed by quantifying the change in body weight, mean survival time, and percent increase in lifespan (%ILS), determining haematological and serum biochemical parameters (liver function test, kidney function test and lipid profile parameters) as well as studying the histopathological alterations in liver tissues. We observed a clear increase in %ILS of the DOX‐SIM‐Solution group (265.30) that was double the %ILS of the DOX‐SIM‐NE group (134.70). However, DOX‐SIM‐NE had a non‐toxic effect on the haematological parameters, whereas DOX‐SIM‐Solution increased the levels of haemoglobin and lymphocytes. Furthermore, the encapsulation of SIM and DOX into NEs improved the levels of all serum biochemical parameters compared to the DOX‐SIM‐Solution. A reduction in the side effects of DOX‐SIM‐NE on the liver was also established using light microscopy, which revealed that the morphologies of the hepatocytes of the mice were less affected by administration of the DOX‐SIM‐NE treatment than with the DOX‐SIM‐Solution treatment. The study showed that incorporating SIM into the DOX‐loaded‐NE formulation remarkably improved its efficiency and simultaneously reduced its adverse effects. 相似文献